Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.
Augustin M, Beier D, Branner J, Häckl D, Hampel R, Kramps T, Kurzen H, Lintener H, Melzer N, Müller M, Staubach P, Schwichtenberg U, Termeer C, Zink A, Nathan P, Maurer M. Augustin M, et al. Among authors: termeer c. J Eur Acad Dermatol Venereol. 2024 May 11. doi: 10.1111/jdv.20071. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38733261
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in Germany.
Maurer M, Augustin M, Bauer S, Ekanayake-Bohlig S, Kircher P, Knöll A, Kramps T, Kurzen H, Laemmel S, Novak N, Oppel E, Pirouzmandi L, Rebhan M, Reimnitz U, Richter-Huhn G, Schwarz B, Schwichtenberg U, Staubach P, Termeer C, Thielen A, Varga K, von Bubnoff D, Zink A, Gmeiner B, Nathan P. Maurer M, et al. Among authors: termeer c. J Eur Acad Dermatol Venereol. 2024 Mar 5. doi: 10.1111/jdv.19940. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38441370
Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS).
Thaҫi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Schäkel K, Wegner S, Krampe S, Bartz H, Rausch C, Taut F, Eyerich K. Thaҫi D, et al. Among authors: termeer c. Br J Dermatol. 2023 Dec 22:ljad523. doi: 10.1093/bjd/ljad523. Online ahead of print. Br J Dermatol. 2023. PMID: 38133615
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Principles, drivers and opportunities of a circular bioeconomy.
Muscat A, de Olde EM, Ripoll-Bosch R, Van Zanten HHE, Metze TAP, Termeer CJAM, van Ittersum MK, de Boer IJM. Muscat A, et al. Among authors: termeer cjam. Nat Food. 2021 Aug;2(8):561-566. doi: 10.1038/s43016-021-00340-7. Epub 2021 Aug 9. Nat Food. 2021. PMID: 37118163 Review.
The framing of malnutrition by parliamentarians in Uganda.
Namugumya BS, Candel JJL, Termeer CJAM, Talsma EF. Namugumya BS, et al. Among authors: termeer cjam. Health Policy Plan. 2021 Jun 3;36(5):585-593. doi: 10.1093/heapol/czab009. Health Policy Plan. 2021. PMID: 33709155
57 results